Rosuvastatin Flexible Chitosomes: Development, In Vitro Evaluation and Enhancement of Anticancer Efficacy Against HepG2 and MCF7 Cell Lines.

MLA

Eleraky, Nermin E., et al. “Rosuvastatin Flexible Chitosomes: Development, In Vitro Evaluation and Enhancement of Anticancer Efficacy Against HepG2 and MCF7 Cell Lines.” AAPS PharmSciTech, vol. 25, no. 7, Oct. 2024, p. 234. EBSCOhost, https://doi.org/10.1208/s12249-024-02957-w.

APA

Eleraky, N. E., Hassan, A. S., Soliman, G. M., Al-Gayyar, M. M. H., & Safwat, M. A. (2024). Rosuvastatin Flexible Chitosomes: Development, In Vitro Evaluation and Enhancement of Anticancer Efficacy Against HepG2 and MCF7 Cell Lines. AAPS PharmSciTech, 25(7), 234. https://doi.org/10.1208/s12249-024-02957-w

Chicago

Eleraky, Nermin E, Abeer S Hassan, Ghareb M Soliman, Mohammed M H Al-Gayyar, and Mohamed A Safwat. 2024. “Rosuvastatin Flexible Chitosomes: Development, In Vitro Evaluation and Enhancement of Anticancer Efficacy Against HepG2 and MCF7 Cell Lines.” AAPS PharmSciTech 25 (7): 234. doi:10.1208/s12249-024-02957-w.